Sensei Biotherapeutics公司宣布,其候选疗法Piktor针对HR阳性、HER2阴性晚期乳腺癌的1B/2期临床试验中期数据,预计将于2027年获得。该数据将提供关于疗法安全性及初步疗效的关键见解。
Sensei Biotherapeutics公司宣布,其候选疗法Piktor针对HR阳性、HER2阴性晚期乳腺癌的1B/2期临床试验中期数据,预计将于2027年获得。该数据将提供关于疗法安全性及初步疗效的关键见解。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.